2014

Actinium Pharmaceutical's Announces Analyst Coverage

BURTON, Mich., Dec. 3, 2013 /PRNewswire/-- Actinium Pharmaceuticals, Inc. (OTCQB: ATNM) a pharmaceutical company developing drugs for treatment of cancer with intent to cure or significantly improve survival of the affected patients announces analyst coverage. Actinium's drugs are monoclonal antibodies labeled with radioisotopes.  The push by large pharmaceuticals companies to acquire smaller biotech businesses to gain new drugs that could bolster income is focusing increasingly on cancer therapy. Actinium has recently been the subject of a well respected analyst research coverage. This report sheds light on Actinium's current progress and future potential. Read this full report here:  http://smallcaptraders.com/is-antm-an-acquisition-target-for-global-pharmaceutical-companies/

SOURCE Actinium Pharmaceuticals, Inc.




Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.